IONS stock news · Ionis Pharmaceuticals, Inc.
Get alerts for IONS
Follow Ionis Pharmaceuticals, Inc. (IONS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IONSIonis Pharmaceuticals shares important news about their study results for sefaxersen.
Good for IONSRoche reported strong Phase 3 results for Ionis's drug sefaxersen. The study is not finished, but the findings make this favorable for Ionis.
The FDA has given the green light to GSK's Hibsago (bepirovirsen) to treat chronic hepatitis B.
Good for IONSThe approval is a win for Ionis's partnership, and the story says Hibsago uses technology Ionis pioneered. It gives no payment or sales details, so the size of any benefit is unknown.
Eli Lilly's stock dropped on Tuesday. What's going on?
Bad for IONSThe article links Ionis to the failed drug program and says the news weighed on the company because of financial ties to pelacarsen.
Robinhood might jump about 23%. Check out 10 expert predictions for Tuesday.
Bad for IONSIonis Pharmaceuticals Inc had its price target cut from $115 to $100 while the analyst kept a Buy rating, indicating a lower valuation view.
Novartis, Ionis Pharmaceuticals, and other major stocks dropped in early trading on Tuesday.
Bad for IONSIonis shares fell in sympathy after Novartis announced the pelacarsen phase III trial missed its primary endpoint, and Novartis holds global rights to the drug.